Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of reslizumab in eosinophilic asthma
NL-OMON36581Phase 3Withdrawn
- Sponsor
- Cephalon, Inc.
- Start
- May 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of reslizumab in asthma and eosinophilic asthma (EA), sponsored by Cephalon, Inc. Primary endpoints: Adverse events, Clinical laboratory tests and 2 more. Planned start May 2011; status: withdrawn.
02
Drugs
reslizumab
03
Conditions
asthmaeosinophilic asthma (EA)
Beyond the preview
Go deeper on NL-OMON36581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36581.